New test may predict who benefits from targeted breast cancer drug
NCT ID NCT05340413
First seen Mar 16, 2026 · Last updated May 15, 2026 · Updated 8 times
Summary
This study tested a new lab test (RAD51-foci) to see if it can predict whether the drug olaparib will shrink tumors in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). The study involved 65 participants and aimed to improve how doctors choose treatments. The main goal was to see if the test could tell which patients would respond best to olaparib.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H Clinic de Barcelona
Barcelona, Spain
-
H Vall d Hebron
Barcelona, Spain
-
H. 12 de Octubre
Madrid, Spain
-
H. C. U. Valencia
Valencia, Spain
-
H. San Cecilio
Granada, Spain
Conditions
Explore the condition pages connected to this study.